FLUENT Corp. operates in the healthcare sector, focusing on the cultivation and distribution of medical cannabis products. The company faces significant concerns, including a low gross margin of 9.2% and a troubling net margin of -83.4%, indicating profitability challenges. Additionally, its current and quick ratios below 1 suggest liquidity issues. The stock's sharp decline of 25% today, combined with a market cap of just $9.57 million, raises red flags about investor confidence and overall financial health.
Loading financial metrics...
Gross profit margin declined from 44.6% to 18.6% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-78.7M over the last year, representing 101.0% of revenue.
Debt of $143.8M is 17.3x the company's cash position of $8.3M.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.1M over the last year.
Exceptional revenue growth of 50.8% YoY demonstrates strong market demand and competitive positioning.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q1 (March 31, 2026)